Stonegate Capital Partners has updated its coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path, a clinical-stage biotechnology company, is pioneering RNA interference therapeutics with its DNAbilize® platform. Key developments include promising Phase 2 data for prexigebersen in AML treatment and early efficacy signs for BP1001-A in solid tumors. For further details, visit: newsfilecorp.com/release/171969.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.